Oral Orforglipron Weight Loss Across Six Trials: Efficacy, GI Tolerability, Gaps
This narrative systematic review consolidates six Eli Lilly-funded randomized trials of the first nonpeptide oral glucagon-like peptide-1 receptor agonist (GLP-1RA) in obesity and type 2 diabetes, giving pharmacists a dose-by-population view of efficacy and tolerability.
📅 Journal publication: Oct 2026(online Oct 11, 2026)·Last updated: Nov 16, 2026
Oral orforglipron shows promise for significant weight reduction.
Managing obesity and type 2 diabetes mellitus (T2DM) often requires long-term injectable medications, which can be a barrier for patients. Orforglipron led to body weight reductions of -4.5% to -14.7%, and improved glycemic and metabolic outcomes, with common gastrointestinal side effects. While promising, more long-term trials are needed to determine optimal dosing and safety, limiting immediate clinical application. Orforglipron shows potential as an oral alternative for managing obesity but requires further study.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Paredes Yacaman GJ, Jiménez López AM, Cordova PR, Abad Cuenca SE, Mora López S, Cobos Lladó AI, Bautista Quintero DO, Castillo Bárcena ED, Zamarripa Mottú RA, Zúñiga Flores V, Flores Valdés JR, Montelongo Quevedo M
Citation:Paredes Yacaman GJ, Jiménez López AM, Cordova PR, et al. Efficacy and Safety of Oral Orforglipron for Weight Reduction in Adults With Overweight or Obesity: A Systematic Review. Cureus. 2026;18(10):e117774. doi:10.7759/cureus.117774